Sign in Subscribe

Corcept's Relacorilant Faces FDA Setback for Hypertension Treatment

FDA issues Complete Response Letter for Corcept's relacorilant despite successful trials, requesting more evidence before approval for hypertension treatment in hypercortisolism patients.

Corcept's Relacorilant Faces FDA Setback for Hypertension Treatment
Credit: Saint John’s Cancer Institute
Already have an account? Sign in.